PARP inhibitor and PD1 in lung squamous cell carcinoma The current study will compare PD1
plus maintenance PARP for the treatment of squamous NSCLC. The study's 2 primary hypotheses
are: respect to progression-free survival (PFS) per RECIST 1.1 by blinded independent
clinical review (BICR).
Overall survival (OS).
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital